Related Experiment Videos
Acute and chronic pulmonary function changes in allergic bronchopulmonary aspergillosis
Abstract:
Pulmonary functions of patients with allergic bronchopulmonary aspergillosis were studied during an acute episode (n = 6); during a mean follow-up period of 44 months (range four months--14.8 years) (n = 16); and for any correlation between duration of ABPA and asthma with the total lung capacity (helium dilution), 1 second forced expiratory volume (FEV1), vital capacity, 1 second forced expiratory volume-forced vital capacity ratio (FEV1:FVC per cent) and diffusing capacity of carbon monoxide (DL:CO) (single breath) for the entire group (n = 22). All patients were treated with corticosteroids (intermittent or continuous) and bronchodilators. For the 16 patients, slopes using linear regression analysis were determined from the function as per cent predicted versus time in months from diagnosis and then analyzed for significance. Significant functional loss was shown in three of 16 patients for FEV1, two of 16 patients for vital capacity, one of 16 patients for FEV1:FVC per cent, none of 10 patients for DL:CO and one of 10 patients for total lung cital capacity, FEV1:FVC per cent and the duration of asthma or allergic bronchopulmonary aspergillosis was found by multiple regression analysis correcting for age and smoking (mean 4.24 years; range 0.3 to 14.8 years). Roentgenographic criteria and blood eosinophilia were used to define a "flare" of allergic bronchopulmonary aspergillosis. The six patients during a flare showed a significant reduction in total lung capacity (P less than 0.001), vital capacity (P less than 0.05), FEV1 (P less than 0.01) and DL:CO (P less than 0.001) which uniformly returned to baseline values during steroid therapy. The FEV1:FVC per cent remained unaltered. These findings, contrary to suggestions in the literature, indicate that in the majority of our patients there was no significant progressive functional deterioration after diagnosis. However, during acute episodes of allergic bronchopulmonary aspergillosis, transient reduction of volumes and DL:CO were uniformly present.
Insights
Pulmonary function tests in allergic bronchopulmonary aspergillosis (ABPA) patients show transient declines during acute episodes. However, most patients do not experience significant progressive functional loss after diagnosis, contrary to some literature suggestions.
Area of Science:
- Pulmonology
- Allergy and Immunology
- Medical Research
Background:
- Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity disorder.
- The long-term impact of ABPA on pulmonary function is not fully understood.
- Previous studies suggested progressive functional deterioration in ABPA patients.
Purpose of the Study:
- To assess pulmonary function in ABPA patients during acute episodes and over time.
- To investigate the correlation between ABPA duration and pulmonary function parameters.
- To determine if ABPA leads to significant progressive lung function loss.
Main Methods:
- Pulmonary function tests including total lung capacity, FEV1, vital capacity, FEV1:FVC ratio, and DL:CO were performed.
- Patients were evaluated during acute flares and followed over a mean of 44 months.
- Linear and multiple regression analyses were used to assess functional changes and correlations.
Main Results:
- Acute ABPA flares were associated with significant transient reductions in lung volumes and DL:CO.
- These reductions returned to baseline with steroid therapy.
- No significant progressive functional deterioration was observed in the majority of patients post-diagnosis.
- FEV1:FVC ratio remained unaltered during flares and over time.
Conclusions:
- ABPA can cause temporary declines in lung function during acute exacerbations.
- Long-term corticosteroid and bronchodilator treatment appears to prevent significant progressive lung function loss in most ABPA patients.
- Findings challenge previous notions of inevitable progressive functional decline in ABPA.